Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
20,761,963
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
2,658,168
-
Shares change
-
+6,120
-
Total reported value, excl. options
-
$7,523,090
-
Value change
-
-$53,802
-
Number of buys
-
3
-
Number of sells
-
8
-
Price
-
$2.83
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q4 2024
As of 31 Dec 2024 CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) had 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,658,168 shares of stock of the company.
Largest 10 holders included Foresite Capital Management VI LLC, VR Adviser, LLC, Woodline Partners LP, Wellington Shields Capital Management, LLC, ADAR1 Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, Wellington Shields & Co., LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, and Royal Bank of Canada.
This table shows 22 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.